Potential biomarkers in saliva for oral squamous cell carcinoma. 2010

Jia-Yo Wu, and Chen Yi, and Ho-Ren Chung, and Duen-Jeng Wang, and Wen-Chien Chang, and Sheng-Yang Lee, and Che-Tung Lin, and Yueh-Chao Yang, and Wei-Chung Vivian Yang
School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan.

Sensitive and reliable early diagnostic markers for oral squamous cell carcinoma (OSCC) remain unavailable. Early identification of recurrence for OSCC is also a challenge. Unlike the other deep cancers, OSCC is located in oral cavity. The DNA, RNA, and protein derived from the living cancer cells and inflammatory cells then can be conveniently obtained from saliva. High-throughput genomic and proteomic approaches have been carried out to identify the potential biomarkers in body fluids such as saliva and blood for diagnosis and prognosis of OSCC. This article reviewed the recently identified biomarkers from saliva for OSCC. In addition, the biomarkers which have been correlated with OSCC tumor malignancy by molecular pathology analysis are also described. Finally, the potential biomarkers that have been demonstrated to associate with the malignant OSCC may be used for salivary screening for high-risk patients are suggested. This article may help to identify the potential biomarkers for screening and the molecular pathology analysis for high-risk patients of OSCC. Effective screening to identify high-risk patients can allow the clinician to provide the appropriate treatment without delay and to reduce the recurrence of OSCC.

UI MeSH Term Description Entries
D008297 Male Males
D009062 Mouth Neoplasms Tumors or cancer of the MOUTH. Cancer of Mouth,Mouth Cancer,Oral Cancer,Oral Neoplasms,Cancer of the Mouth,Neoplasms, Mouth,Neoplasms, Oral,Cancer, Mouth,Cancer, Oral,Cancers, Mouth,Cancers, Oral,Mouth Cancers,Mouth Neoplasm,Neoplasm, Mouth,Neoplasm, Oral,Oral Cancers,Oral Neoplasm
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D012463 Saliva The clear, viscous fluid secreted by the SALIVARY GLANDS and mucous glands of the mouth. It contains MUCINS, water, organic salts, and ptylin. Salivas
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D018570 Risk Assessment The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988) Assessment, Risk,Benefit-Risk Assessment,Risk Analysis,Risk-Benefit Assessment,Health Risk Assessment,Risks and Benefits,Analysis, Risk,Assessment, Benefit-Risk,Assessment, Health Risk,Assessment, Risk-Benefit,Benefit Risk Assessment,Benefit-Risk Assessments,Benefits and Risks,Health Risk Assessments,Risk Analyses,Risk Assessment, Health,Risk Assessments,Risk Benefit Assessment,Risk-Benefit Assessments

Related Publications

Jia-Yo Wu, and Chen Yi, and Ho-Ren Chung, and Duen-Jeng Wang, and Wen-Chien Chang, and Sheng-Yang Lee, and Che-Tung Lin, and Yueh-Chao Yang, and Wei-Chung Vivian Yang
January 2017, Proceedings of the National Academy of Sciences of the United States of America,
Jia-Yo Wu, and Chen Yi, and Ho-Ren Chung, and Duen-Jeng Wang, and Wen-Chien Chang, and Sheng-Yang Lee, and Che-Tung Lin, and Yueh-Chao Yang, and Wei-Chung Vivian Yang
October 2015, Proteomics,
Jia-Yo Wu, and Chen Yi, and Ho-Ren Chung, and Duen-Jeng Wang, and Wen-Chien Chang, and Sheng-Yang Lee, and Che-Tung Lin, and Yueh-Chao Yang, and Wei-Chung Vivian Yang
April 2018, Oral diseases,
Jia-Yo Wu, and Chen Yi, and Ho-Ren Chung, and Duen-Jeng Wang, and Wen-Chien Chang, and Sheng-Yang Lee, and Che-Tung Lin, and Yueh-Chao Yang, and Wei-Chung Vivian Yang
January 2014, Clinica chimica acta; international journal of clinical chemistry,
Jia-Yo Wu, and Chen Yi, and Ho-Ren Chung, and Duen-Jeng Wang, and Wen-Chien Chang, and Sheng-Yang Lee, and Che-Tung Lin, and Yueh-Chao Yang, and Wei-Chung Vivian Yang
November 2023, Heliyon,
Jia-Yo Wu, and Chen Yi, and Ho-Ren Chung, and Duen-Jeng Wang, and Wen-Chien Chang, and Sheng-Yang Lee, and Che-Tung Lin, and Yueh-Chao Yang, and Wei-Chung Vivian Yang
January 2016, Acta odontologica Scandinavica,
Jia-Yo Wu, and Chen Yi, and Ho-Ren Chung, and Duen-Jeng Wang, and Wen-Chien Chang, and Sheng-Yang Lee, and Che-Tung Lin, and Yueh-Chao Yang, and Wei-Chung Vivian Yang
December 2021, Bioengineered,
Jia-Yo Wu, and Chen Yi, and Ho-Ren Chung, and Duen-Jeng Wang, and Wen-Chien Chang, and Sheng-Yang Lee, and Che-Tung Lin, and Yueh-Chao Yang, and Wei-Chung Vivian Yang
February 2015, Proteomics. Clinical applications,
Jia-Yo Wu, and Chen Yi, and Ho-Ren Chung, and Duen-Jeng Wang, and Wen-Chien Chang, and Sheng-Yang Lee, and Che-Tung Lin, and Yueh-Chao Yang, and Wei-Chung Vivian Yang
January 2021, Translational cancer research,
Jia-Yo Wu, and Chen Yi, and Ho-Ren Chung, and Duen-Jeng Wang, and Wen-Chien Chang, and Sheng-Yang Lee, and Che-Tung Lin, and Yueh-Chao Yang, and Wei-Chung Vivian Yang
April 2021, Journal of clinical medicine,
Copied contents to your clipboard!